c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 148 produtos para "c-Met/HGFR".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Cor e Forma:White SolidPeso molecular:518.559Emibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Pureza:96.5% (SDS-PAGE); 98.8% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.9% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:143.74 kDa (Predicted)SU 5616
CAS:SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.Fórmula:C13H8ClNOSPureza:98.84%Cor e Forma:SolidPeso molecular:261.727Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Pureza:97.3%Cor e Forma:Transparent LiquidPeso molecular:146.99 kDa (Predicted)c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Fórmula:C17H14N8SPureza:98.77%Cor e Forma:SolidPeso molecular:362.412CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Fórmula:C20H20FN7O2Pureza:99.29%Cor e Forma:SolidPeso molecular:409.4169JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Cor e Forma:Yellow SolidPeso molecular:374.3463Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Fórmula:C20H15F3N8Pureza:99.16%Cor e Forma:SolidPeso molecular:424.3819Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Cor e Forma:Transparent LiquidPeso molecular:145.2 kDa (Predicted)PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Fórmula:C51H50F2N6O13Cor e Forma:SolidPeso molecular:992.97c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Cor e Forma:Odour SolidFosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Fórmula:C16H13N7OPeso molecular:319.11816Zurletrectinib
CAS:Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.Fórmula:C19H19F2N7O2Cor e Forma:SolidPeso molecular:415.4Caveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFórmula:C124H170N28O29Pureza:98%Cor e Forma:SolidPeso molecular:2516.85PROTAC c-Met Degrader-4
CAS:PROTACc-Met Degrader-4 (compound D15) is a potent and orally active PROTACc-MET degrader. It demonstrates exceptional intracellular degradation activity with a DC50 of less than 0.5 nM. This compound can induce cell cycle arrest and apoptosis (apoptosis), inhibit cell invasion and migration, thereby suppressing cell proliferation. It also inhibits the growth of Hs746T xenograft tumors in nude mice. PROTACc-Met Degrader-4 is applicable in cancer research, including studies on non-small cell lung cancer and gastric cancer.Fórmula:C47H44N10O7Pureza:97.19%Peso molecular:860.93PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Cor e Forma:SolidPeso molecular:919.037LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Fórmula:C18H11F3N4OPureza:99.58%Cor e Forma:Yellow SolidPeso molecular:356.3Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.Fórmula:C41H58N8O7Pureza:98%Cor e Forma:SolidPeso molecular:774.95PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56
